Termination Agreement and Release dated September 19, 2022 by and between iBio, Inc. and RubrYc Therapeutics, Inc
Exhibit 10.2
TERMINATION AGREEMENT AND RELEASE
This Termination Agreement AND RELEASE (this “Termination Agreement”) is entered into as of the 19th day of September, 2022 between iBio, Inc., a Delaware corporation (“iBio”) and RubrYc Therapeutics, Inc., a Delaware corporation (“RubrYc”). Each of iBio and RubrYc are referred to herein as a “Party” or, collectively, as the “Parties.”
RECITALS
WHEREAS, the Parties hereto are parties to that certain Collaboration and License Agreement dated as of August 23, 2021 (the “Collaboration and License Agreement”);
WHEREAS, the Parties hereto are parties to that certain Collaboration, Option and License Agreement dated as of August 23, 2021 (the “Option Agreement”, and together with the Collaboration and License Agreement, the “Agreements”); and
WHEREAS, in connection with that certain Asset Purchase Agreement, dated September 16, 2022, by and between iBio and RubrYc (the “Purchase Agreement”), the Parties hereto desire to terminate the Agreements in accordance with the terms and subject to the conditions set forth in this Termination Agreement.
AGREEMENT
NOW, THEREFORE, the undersigned, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, hereby agree as follows:
2
[Signature page follows.]
3
IN WITNESS WHEREOF, the parties hereto have executed this Termination Agreement as of the date first written above.
RUBRYC THERAPEUTICS, INC.
By: /s/ Isaac Bright
Name: Isaac Bright
Title: Chief Executive Officer
IBIO, INC.
By: /s/ Thomas F. Isett
Name: Thomas F. Isett
Title: Chief Executive Officer
[Signature Page to Termination Agreement]